Business Description

West Pharmaceutical Services Inc
NAICS : 339112
SIC : 3841
ISIN : US9553061055
Share Class Description:
STU:WPS: Ordinary SharesDescription
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.61 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.41 | |||||
Interest Coverage | 117.56 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 17.74 | |||||
Beneish M-Score | -2.58 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.4 | |||||
3-Year EBITDA Growth Rate | 17.9 | |||||
3-Year EPS without NRI Growth Rate | 19.3 | |||||
3-Year FCF Growth Rate | 11.9 | |||||
3-Year Book Growth Rate | 16.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.35 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.37 | |||||
9-Day RSI | 60.97 | |||||
14-Day RSI | 59.07 | |||||
6-1 Month Momentum % | -17.7 | |||||
12-1 Month Momentum % | -8.03 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3 | |||||
Quick Ratio | 2.23 | |||||
Cash Ratio | 0.95 | |||||
Days Inventory | 82.49 | |||||
Days Sales Outstanding | 64.94 | |||||
Days Payable | 44.36 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.26 | |||||
Dividend Payout Ratio | 0.12 | |||||
3-Year Dividend Growth Rate | 5.8 | |||||
Forward Dividend Yield % | 0.27 | |||||
5-Year Yield-on-Cost % | 0.32 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 3.35 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 34.87 | |||||
Operating Margin % | 20.44 | |||||
Net Margin % | 17.37 | |||||
FCF Margin % | 11.16 | |||||
ROE % | 18.16 | |||||
ROA % | 13.61 | |||||
ROIC % | 18.1 | |||||
3-Year ROIIC % | 31.48 | |||||
ROC (Joel Greenblatt) % | 27.61 | |||||
ROCE % | 19.14 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 46.05 | |||||
Forward PE Ratio | 44.51 | |||||
PE Ratio without NRI | 45.92 | |||||
Shiller PE Ratio | 58.47 | |||||
Price-to-Owner-Earnings | 54.04 | |||||
PEG Ratio | 2.09 | |||||
PS Ratio | 7.99 | |||||
PB Ratio | 8.18 | |||||
Price-to-Tangible-Book | 8.55 | |||||
Price-to-Free-Cash-Flow | 71.49 | |||||
Price-to-Operating-Cash-Flow | 32.73 | |||||
EV-to-EBIT | 37.95 | |||||
EV-to-Forward-EBIT | 33.63 | |||||
EV-to-EBITDA | 30.21 | |||||
EV-to-Forward-EBITDA | 26.63 | |||||
EV-to-Revenue | 7.75 | |||||
EV-to-Forward-Revenue | 7.26 | |||||
EV-to-FCF | 69.32 | |||||
Price-to-Projected-FCF | 3.26 | |||||
Price-to-DCF (Earnings Based) | 1.47 | |||||
Price-to-DCF (FCF Based) | 2.29 | |||||
Price-to-Median-PS-Value | 1.32 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.85 | |||||
Price-to-Graham-Number | 4.18 | |||||
Price-to-Net-Current-Asset-Value | 35.84 | |||||
Earnings Yield (Greenblatt) % | 2.64 | |||||
FCF Yield % | 1.43 | |||||
Forward Rate of Return (Yacktman) % | 17.45 |